Cell Source, Inc. (OTC: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine. The company’s patented “Veto-Cell” technology represents a major breakthrough in immune system management – safe and selective “tolerizing” of immune response. This technology addresses one of the most fundamental challenges in human immunology: how to tune immune response so that it tolerates specific “desirable” foreign cells while continuing to attack all other potential threats. For more information, visit the company’s website at www.cell-source.com